Cardiovascular disease, largely because of disruption of atherosclerotic lesions, accounts for the majority of deaths in people with type 1 diabetes. Recent mouse models have provided insights into the accelerated atherosclerotic lesion initiation in diabetes, but it is unknown whether diabetes directly worsens more clinically relevant advanced lesions. We therefore used an LDL receptordeficient mouse model, in which type 1 diabetes can be induced at will, to investigate the effects of diabetes on preexisting lesions. Advanced lesions were induced by feeding mice a high-fat diet for 16 weeks before induction of diabetes. Diabetes, independently of lesion size, increased intraplaque hemorrhage and plaque disruption in the brachiocephalic artery of mice fed low-fat or high-fat diets for an additional 14 weeks. Hyperglycemia was not sufficient to induce plaque disruption. Furthermore, diabetes resulted in increased accumulation of monocytic cells positive for S100A9, a proinflammatory biomarker for cardiovascular events, and for a macrophage marker protein, without increasing lesion macrophage content. S100A9 immunoreactivity correlated with intraplaque hemorrhage. Aggressive lowering primarily of triglyceride-rich lipoproteins prevented both plaque disruption and the increased S100A9 in diabetic atherosclerotic lesions. Conversely, oleate promoted macrophage differentiation into an S100A9-positive population in vitro, thereby mimicking the effects of diabetes. Thus, diabetes increases plaque disruption, independently of effects on plaque initiation, through a mechanism that requires triglyceride-rich lipoproteins and is associated with an increased accumulation of S100A9-positive monocytic cells. These findings indicate an important link between diabetes, plaque disruption, and the innate immune system. intraplaque hemorrhage ͉ macrophage ͉ S100A9
T
he risk for cardiovascular events is up to 10-fold higher than normal in people with type 1 diabetes, largely because of underlying atherosclerosis (1) . This excess risk is most likely not explained by hypercholesterolemia, one major risk factor for atherosclerosis, because cholesterol levels are similar in people with type 1 diabetes and the general population (2) . However, plasma triglycerides are commonly increased in inadequately treated patients with suboptimal glycemic control (2) . Suboptimal blood glucose control is associated with increased cardiovascular risk in type 1 diabetes (3), as is renal dysfunction (4) . Furthermore, when present, common risk factors, such as elevated LDL and hypertension, contribute to cardiovascular disease in patients with type 1 diabetes, as in the general population.
The cellular mechanisms whereby diabetes promotes atherosclerosis remain poorly understood, although several animal models exist for studies of lesion initiation (5) . Most acute cardiovascular events in humans are precipitated by rupture/ fissuring of advanced lesions (6) . It is not known whether diabetes has direct detrimental effects on such lesions. Ruptureprone lesions are rich in activated macrophages. These cells have a number of proposed roles in plaque disruption, including the production of inflammatory mediators regulating the balance between synthesis and degradation of matrix components. Interestingly, it is becoming increasingly clear that monocytes/ macrophages secrete increased levels of proinflammatory mediators in patients and animals with type 1 diabetes (7-9), which might negatively impact the fate of advanced lesions of atherosclerosis. One of these proinflammatory mediators is S100A9 (9) , a protein expressed in monocytes and neutrophils and recently identified as a biomarker for cardiovascular events (10) (11) (12) .
To examine the effects of diabetes on advanced lesions without confounding effects on lesion initiation, we used an LDL receptor (LDLR)-deficient model of type 1 diabetes (13) . In this LDLR Ϫ/Ϫ ;GP mouse, type 1 diabetes can be induced by lymphocytic choriomeningitis virus (LCMV) infection, which causes T cell-mediated destruction of ␤-cells, because of expression of an LCMV glycoprotein (GP) transgene controlled by the insulin promoter. This model closely mimics the autoimmune destruction of ␤-cells in human type 1 diabetes. Our results show that diabetes increases plaque disruption, independently of effects on plaque initiation and size, through a mechanism associated with an increased accumulation of S100A9-positive monocytic cells.
Results
We first examined low-fat-fed mice with preexisting advanced atherosclerotic lesions (Fig. 1a) . Atherosclerotic lesions were evaluated in the aorta and brachiocephalic artery (BCA), an artery prone to developing advanced lesions and plaque rupture/ fissuring (13, 14) . At the end of a 16-week fat-feeding period, BCA lesions were advanced, with well developed necrotic cores, cholesterol clefts, and fibrous caps [ Fig. 1b and supporting information (SI) Table 1] . The mice were then switched to a low-fat diet for the next 14 weeks, and diabetes was induced 2 weeks after the diet switch. Blood glucose levels increased after induction of diabetes (Fig. 1c) . Plasma insulin levels were similar in nondiabetic and diabetic mice (SI Table 2 ), because diabetic mice required exogenous insulin treatment to prevent weight loss and ketonuria (13) . Blood cholesterol levels increased during the fat-feeding period and declined in both nondiabetic and diabetic mice after the switch to a low-fat diet. Diabetic mice showed only slight elevations in cholesterol ( Fig. 1 d and e) , but significantly elevated triglycerides (Fig. 1f ) , much like inadequately treated humans with type 1 diabetes.
BCA cross-sectional lesion area, at the site of maximal lesion, was evaluated after the 16-week fat-feeding period and then again after the 14-week low-fat diet period. BCA lesion and lumen area were similar in diabetic and nondiabetic littermates, although lesion area was greater than in the 16-week baseline group ( Fig. 1 g and h) . Diabetic and nondiabetic mice differed in plaque morphology, however, because, compared with nondiabetic mice ( Fig. 1 i and k) , diabetic mice had more intraplaque hemorrhage in the shoulder regions of plaques ( Fig. j and l) , determined by the presence of erythrocytes, visualized by Movat's pentachrome stain. The presence of intraplaque erythrocyte membranes was shown by the erythrocyte marker protein TER-119 in diabetic mice (Fig. 1n ), but not in nondiabetic mice (Fig. 1m) . The increased frequency of intraplaque hemorrhage and plaque disruption (Fig. 1o) was not associated with increased macrophage content (Fig. 1p) , decreased ␣-actin-positive smooth muscle cells, increased necrotic cores (SI Table 1 ), or changes in lesion size. Instead, diabetes resulted in a reduction in Mac-2-positive cells in BCA lesions (Fig. 1p) , consistent with a reduced aortic Sudan IV-positive area (SI Fig. 6 ), where the Sudan IV primarily stains macrophage-rich areas. Thus, the effect of diabetes on plaque disruption was not caused by a general acceleration of plaque progression or increased macrophage content.
We next addressed whether dyslipidemia or hyperglycemia could explain the effect of diabetes on plaque disruption. If dyslipidemia were the culprit, aggressive lipid lowering should reduce intraplaque hemorrhage in fat-fed diabetic mice. Conversely, if hyperglycemia were sufficient, then aggressive lipid lowering should not affect intraplaque hemorrhage. Aggressive lipid lowering was achieved by using a helper-dependent adenovirus to stably overexpress the murine VLDL receptor (HDAd-mVLDLR) in the liver (SI Fig. 7 ). The study design (Fig. 2a) was identical to that used in Fig. 1 , except that nondiabetic and diabetic mice were fed a medium-fat diet for the last 14 weeks of the study. The study also included mice injected with LCMV We have previously shown that LCMV per se does not affect plasma glucose and lipid levels, or lesion size, and that the effects of diabetes can be normalized by intensive insulin treatment after induction of overt diabetes (13) . Consistently, LCMV did not affect size or morphology of advanced lesions, body weight, or plasma lipid levels in the present study (SI Table 3 ). Induction of diabetes caused similar hyperglycemia in controls and HD-Ad-mVLDLR-treated mice (Fig. 2b) . Diabetic mice fed a medium-fat diet were severely dyslipidemic compared with their nondiabetic littermates, but their cholesterol levels, VLDL and LDL, and triglyceride levels were normalized by HD-AdmVLDLR treatment (Fig. 2 c-e) . Mice treated with an empty control virus (HD-Ad-0) did not differ from untreated mice (SI Table 4 ).
The BCA cross-sectional area was larger, and the lumen was smaller, in fat-fed diabetic mice than in nondiabetic mice ( Fig.  2 f and g ). Diabetic mice often showed nearly occluded BCAs compared with nondiabetic mice (Fig. 2 i vs. h) . As in the low-fat fed mice, diabetes increased intraplaque hemorrhage (Fig. 3a) , without increasing relative macrophage content (Fig. 3b) or other characteristics of advanced lesions (SI Table 5 ). HD-AdmVLDLR treatment of diabetic mice normalized BCA lesion and lumen areas (Fig. 2 f, g, j, and k) , and abolished intraplaque hemorrhage (Fig. 3 a, c-f ). Thus, dyslipidemia is required for diabetes-induced plaque disruption, whereas hyperglycemia alone is not sufficient to induce plaque disruption.
Because plaque disruption occurred primarily in the macrophage-rich lesion shoulders, we next asked whether the increased intraplaque hemorrhage could be caused by differences in the cell population infiltrating lesions in diabetes. S100A9, a protein expressed in monocytes and neutrophils but absent in resident macrophages (11, 12) , was used as a marker. We also investigated monocytes/macrophages positive for the Ly-6C antigen, which were recently shown to preferentially infiltrate lesions in fat-fed nondiabetic mice (15, 16) .
S100A9 immunoreactivity was present primarily in the disruption-prone lesion shoulders in nondiabetic and diabetic mice (Fig. 4 a and b) , was specific to the anti-S100A9 antibody (Fig.  4c) , and colocalized with Mac-2-positive cells in the shoulder areas, but was lost in Mac-2-positive cells deeper within the lesion (Fig. 4 d and e) . Few cells expressed the Ly-6C antigen, and S100A9-positive cells did not appear to be restricted to Ly-6C-positive cells (data not shown). Furthermore, there was significantly more S100A9 immunoreactivity in lesions from diabetic mice than in nondiabetic mice (Fig. 4f ) . Plasma levels of serum amyloid A (SAA) were similar in nondiabetic and diabetic animals, indicating that the increase in S100A9 was not due to systemic inflammation (SI Table 2 ). Consistent with the ability of aggressive lipid lowering to reduce intraplaque hemorrhage in diabetic mice, hepatic overexpression of mVLDLR reduced S100A9 immunoreactivity in lesions of diabetic mice (Fig. 4f ) . Indeed, a significant correlation between lesion S100A9 immunoreactivity and intraplaque hemorrhage was observed (P ϭ 0.002; Spearman r ϭ 0.38).
To determine whether diabetes itself might affect S100A9, we quantified cellular levels of S100A9 in isolated peritoneal monocytes/macrophages after thioglycollate injection. Adhesion-purified thioglycollate-elicited peritoneal macrophages from diabetic mice fed the low-fat diet expressed more S100A9 than macrophages from nondiabetic mice (Fig. 4 g and  h) . Blood glucose and cholesterol levels in these mice (SI Table  6 ) were similar to those of the mice shown in Fig. 1 . Parallel proteomics studies identified S100A9 as the protein with the largest increase in secretion from thioglycollate-elicited monocytes/macrophages from diabetic compared with nondiabetic mice (SI Fig. 8 
and SI Text).
To determine whether S100A9-positive cells might express higher levels of proteases that could contribute to plaque disruption, we next analyzed bone marrow-derived cells during differentiation into macrophages. Both S100A9 and matrix metalloproteinase-9 (MMP-9) gene expression, and MMP-9 activity, were rapidly reduced with time ( Fig. 5 a-c) , suggesting that an S100A9-positive and MMP-9-positive macrophage population was not expanded during these basal conditions. S100A9 and MMP-9 were coexpressed in cell populations characterized by Ly-6C, CD115, and CD11b gene expression (Fig. 5a) . To investigate the mechanism whereby diabetes might promote expansion of an inflammatory and proteolytically active cell population, bone marrow-derived cells were allowed to differentiate in the presence of M-CSF plus fatty acids or elevated glucose levels. Interestingly, whereas elevated glucose (25 mmol/ liter) failed to sustain S100A9-and MMP-9-positive populations, oleic acid, one of the most common fatty acids in circulation, prevented the loss of both S100A9 and MMP-9 (Fig. 5d) . In addition, there was a significant correlation between plasma triglyceride levels and the inflammation marker sICAM-1 in diabetic mice, whereas no such correlation was observed for glucose (SI Fig. 9 ).
Discussion
This study addresses the effects of diabetes on advanced lesions of atherosclerosis, without confounding effects on lesion initiation, and shows that type 1 diabetes promotes disruption of advanced atherosclerotic lesions through a mechanism that requires plasma triglyceride levels to be above Ϸ2 mmol/liter. Diabetic mice showed elevated plasma triglyceride levels compared with nondiabetic controls, both when fed low-fat and medium-fat diets. The main lipid abnormality in diabetic mice in this model is an elevation of triglyceride-rich lipoproteins, consistent with the elevated triglycerides seen in patients with type 1 diabetes (2). Furthermore, aggressive lowering of triglyceride-rich lipoproteins by hepatic overexpression of the VLDLR abolished the effect of diabetes on plaque disruption. Although hyperglycemia might contribute to plaque disruption, it was clearly not sufficient. The effect of diabetes was independent of lesion size, total macrophage content, and other morphological features of advanced lesions. Thus, diabetes appears to specifically promote plaque disruption in this model.
At a cellular level, our observations suggest that diabetes results in an increased recruitment of an S100A9-positive monocyte/macrophage population, or possibly a neutrophil-like population, into lesions, and that these cells contribute to plaque disruption. S100A9 has been shown to colocalize with macrophage markers, but not neutrophil markers, in atherosclerotic lesions (17, 18) , and to be expressed at increased levels in unstable versus stable areas of human plaques (19) . Human monocytes and neutrophils express high levels of S100A9 at a maturation stage that coincides with CD11b expression, whereas lymphocytes, erythrocytes, and resident macrophages are S100A9-negative (11, 12) . In humans with type 1 diabetes, increased S100A9 is seen in circulating monocytes (9) and in plasma (20) . The reason for this will require further investigation, but it is possible that the increased infiltration of S100A9-positive monocytes/macrophages into sites of inflammation in diabetes is due to an increased S100A9 expression in circulating monocytes or expansion of an S100A9-positive monocyte/ macrophage population. Interestingly, our results suggest that common fatty acids (oleic acid), but not elevated glucose levels, mimic the effects of diabetes on maintaining or expanding an S100A9-and MMP-9-positive macrophage-like population in vitro, raising the possibility that elevated fatty acids and/or triglycerides might mediate the effects of diabetes on inflammatory properties of macrophages. The correlation between plasma triglycerides and sICAM-1, another marker of inflammation, in diabetic mice is consistent with this idea. Does S100A9 directly contribute to plaque disruption, or is it a marker of a distinct cell population? Data showing that exogenous S100A9 exerts proinflammatory effects in vascular cells (21, 22) and that S100A9 activates Toll-like receptor 4 (23) and is required for MMP-2 expression in gastric cancer cells (24) indicate that it might play a role in plaque disruption. However, equally interesting is the possibility that it serves as a marker of a more proteolytically active macrophage population. Our data show that MMP-9 expression and activity closely correlate with S100A9 expression. MMP-9 is also expressed in a subset of macrophages (25) . Recent studies indicate that macrophages expressing active MMP-9 promote plaque disruption in apoEdeficient mice (26) . Future studies will be required to evaluate the role of inflammatory and MMP-9-expressing cell populations in plaque disruption in diabetic mice.
Regardless of the role of S100A9 as a marker or a mediator of plaque disruption, these results show that type 1 diabetes directly promotes disruption of advanced plaques. Intraplaque hemorrhage in the mouse BCA is most likely caused by disruption of the macrophage-rich shoulder regions, because microvessels are undetectable in these areas (14) . Conversely, leaking vasa vasorum contributes to intraplaque hemorrhage in lesions of larger vessels in mice (27) and humans (28) . Despite the plaque disruption in mice, arterial thrombosis and subsequent cardiovascular events are rarely observed (13, 26, 29) . Current mouse models thus provide insights into plaque disruption, but not arterial thrombosis. Further studies will be needed to address the applicability of our findings in humans.
In summary, our observations indicate that diabetes promotes accumulation of an S100A9-positive macrophage population in atherosclerotic lesions and other inf lamed tissues. Raising the possibility that these cells promote plaque disruption in diabetes.
Materials and Methods
Study Design. Female LDLR Ϫ/Ϫ mice expressing the LCMV GP transgene under control of the insulin promoter were used, as described in ref. 13 . These mice (termed LDLR Ϫ/Ϫ ;GP) develop type 1 diabetes when infected with LCMV. Mice received semipurified diets; a low-fat cholesterol-free diet containing 10.8% fat calories, a medium-fat diet containing 0.12% cholesterol and 20.0% fat calories, or a high-fat diet containing 1.25% cholesterol and 40.0% fat calories (TD00241, TD04018, and TD00244, respectively; Harlan Teklad).
To study the effects of diabetes on preexisting advanced lesions, mice were fed the high-fat diet for 16 weeks and then switched to low-fat or medium-fat diets for the next 14 weeks. Some mice were injected i.p. with LCMV (1 ϫ 10 5 PFU) to induce diabetes at week 18, whereas littermates remained nondia- betic because they were injected with saline. At the same time, some mice were injected through the tail vein with HD-Ad-mVLDLR or an empty control virus, HD-Ad-0 (3 ϫ 10 11 particles per mouse). A subset of LDLR Ϫ/Ϫ ;GP mice fed the low-fat diet (seven mice per group) was injected peritoneally with thioglycollate after 4 weeks of diabetes, as described in ref. 30 . The monocytes/macrophages were adhesion-purified for 1 h in the presence of serum-free RPMI and harvested for Western blot analysis. Bone marrow was harvested from femurs of C57BL/6 mice and allowed to differentiate into macrophages in the presence of 15% L-conditioned medium, as a source of macrophage colony-stimulating factor (M-CSF). Other methods have been described (13, 31) , or are described in SI Text.
Statistical Analysis. Results are expressed as means Ϯ SEM or scatterplots. Statistical analyses were performed using Prism 3.0 (GraphPad Software), as described in the figure legends. The numbers of mice per group are shown in Figs. 1 and 2 .
